GenF20 Plus review (2026): what its randomized trial actually found
Last updated: September 22, 2026 · NADPrime Editorial Team
NADPrime editorial score: 4.6/5. This is our editorial assessment, not a customer rating or clinical effectiveness grade.
What the evidence actually supports
The study randomized 70 adults ages 35-65; 61 completed and were analyzed. Serum IGF-1 was the primary endpoint. Mean IGF-1 increased in both groups, and the overall between-group difference was not statistically significant. In the age-40+ subgroup, the unadjusted comparison was also not significant; an ANCOVA adjusted for baseline values reported a significant difference favoring GenF20 Plus.
That makes the formula trial relevant but limited. It should not be summarized as proof that the product "raises HGH" or delivers the full set of anti-aging outcomes advertised by the manufacturer.
| Study design | Randomized, double-blind, placebo-controlled; 12 weeks. |
| Participants | 70 randomized; 61 completed and were analyzed. |
| Primary endpoint | Serum IGF-1, not circulating HGH. |
| Overall result | Between-group IGF-1 difference was not statistically significant. |
| 40+ subgroup | Adjusted ANCOVA result favored GenF20 Plus; interpret as subgroup evidence, not the overall trial result. |
| Return terms | Manufacturer advertises a 67-day money-back guarantee; verify live conditions. |
What we like
- A published trial evaluated the complete product
- Study design was randomized and double-blind
- Manufacturer provides a relatively long refund window
Important limits
- Overall primary between-group comparison was not statistically significant
- Other measured outcomes did not significantly differ from placebo
- Study measured IGF-1 rather than direct circulating HGH
- Independent replication would strengthen confidence
What this product should not be used to self-diagnose
Low energy, poor sleep, low libido or body-composition changes are not a home diagnosis of growth-hormone deficiency. True GH disorders require clinical evaluation and appropriate testing.
Frequently asked questions
Did the study prove GenF20 Plus raises HGH?
No. The study measured IGF-1 as its primary endpoint, not circulating HGH directly.
Was the overall trial statistically significant?
The overall between-group IGF-1 difference was not statistically significant. An adjusted analysis in the 40+ subgroup favored the product.
Did the trial show better sleep, libido, body fat or muscle than placebo?
The publication reported no statistically significant between-group differences for the other measured outcomes.
How long is the current return window?
The manufacturer currently advertises 67 days, with conditions. Verify the live policy before ordering.
Before buying: Verify the live product label, price, subscription terms and refund conditions on the manufacturer's site. If you take medication, have a health condition, are pregnant or breastfeeding, or have persistent unexplained symptoms, talk with a qualified healthcare professional before using a supplement.